Compare Eli Lilly And Co (LLY) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.74 (market cap $168.50B). The key difference: Eli Lilly And Co is far larger — about 6.2× Vanguard Emerging Markets Stock Index Fund ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| LLY | VWO | |
|---|---|---|
Market Cap | $1.04T | $168.50B |
Volume | 3,064,878 | 9,650,999 |
Sector | Health | — |
52-Week High | $1.28K | $61.44 |
52-Week Low | $799.57 | $52.42 |
Typical Hold Time | 93 Days | 135 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
VWO trades at $59.67, down 0.3% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic slowdown weighs on performance. Recent news highlights institutional accumulation with Allianz and Alamar Capital increasing positions, though comparisons show developed market ETFs like VEA offer lower expense ratios and higher yields.
Outlook remains cautious with technical resistance at $60 and support at $59. Emerging markets face headwinds from China's weak retail and property sectors, though AI infrastructure spending offers partial offset. Investors should monitor dollar weakness as a potential catalyst for EM equities while weighing concentration risks in single-country exposures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
